InterMune to chop 60 workers in wake of FDA’s rejection

Faced with a recent FDA demand for a new trial of its lung drug pirfenidone, InterMune has brought out the budget axe. The Brisbane, CA-based developer (ITMN) says it is cutting 40 percent of its workforce, or 60 people. It's a far cry from InterMune's preliminary plans to double or perhaps even triple its workforce if it won an approval. Now InterMune is projecting that the cuts can save the developer $12 million a year after taking a special charge of $2.4 million in the second quarter....

InterMune soars on promising hep C trial

InterMune has announced positive results from a mid-stage study of danoprevir, a potential treatment for hepatitis C. The news sent the company's shares to their highest in eight years, according to Reuters. The study is comparing danoprevir administered for 12 weeks in combination with Pegasys (pegylated interferon alfa-2a) and Copegus (ribavirin) with placebo. Results from the study showed that the drug delivered virologic response in 88 percent of patients treated with 300 mg dosage for...